

Jose Luis Perez-Gracia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9546999/publications.pdf>

Version: 2024-02-01

184
papers

22,039
citations

34105

52
h-index

9589

142
g-index

192
all docs

192
docs citations

192
times ranked

28723
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1540-1550.	13.7	5,456
2	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	13.7	3,077
3	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	13.7	1,728
4	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 81-88.	3.7	816
5	Cytokines in clinical cancer immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 6-15.	6.4	720
6	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	28.4	576
7	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. <i>Nature Medicine</i> , 2019, 25, 470-476.	30.7	459
8	Direct Effects of Type I Interferons on Cells of the Immune System. <i>Clinical Cancer Research</i> , 2011, 17, 2619-2627.	7.0	390
9	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. <i>Immunity</i> , 2020, 52, 856-871.e8.	14.3	387
10	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2017, 28, 1988-1995.	1.2	326
11	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. <i>Nature</i> , 2019, 569, 428-432.	27.8	313
12	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). <i>Clinical Cancer Research</i> , 2016, 22, 3924-3936.	7.0	306
13	Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. <i>Nature Medicine</i> , 2020, 26, 688-692.	30.7	296
14	Interleukin-8 in cancer pathogenesis, treatment and follow-up. <i>Cancer Treatment Reviews</i> , 2017, 60, 24-31.	7.7	262
15	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5461-5471.	7.0	234
16	Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. <i>Clinical Chemistry</i> , 2015, 61, 297-304.	3.2	221
17	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 4663-4673.	7.0	210
18	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. <i>Clinical Cancer Research</i> , 2014, 20, 5697-5707.	7.0	200

#	ARTICLE	IF	CITATIONS
19	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. <i>Annals of Oncology</i> , 2017, 28, 3044-3050.	1.2	198
20	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	9.4	197
21	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. <i>Cancer Research</i> , 2016, 76, 5994-6005.	0.9	191
22	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1580-1590.	1.6	189
23	Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. <i>British Journal of Cancer</i> , 2009, 100, 1111-1119.	6.4	183
24	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. <i>Seminars in Oncology</i> , 2015, 42, 640-655.	2.2	179
25	Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii44-xii55.	1.2	170
26	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. <i>Clinical Cancer Research</i> , 2013, 19, 997-1008.	7.0	161
27	The HIF-1 Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy. <i>Cancer Discovery</i> , 2012, 2, 608-623.	9.4	156
28	Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2001, 93, 31-38.	6.3	152
29	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1718-1732.	1.1	141
30	Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes. <i>Cancer Research</i> , 2011, 71, 801-811.	0.9	137
31	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 ^{-/-} /IL2R ³ null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.9	137
32	Circulating melanoma exosomes as diagnostic and prognosis biomarkers. <i>Clinica Chimica Acta</i> , 2016, 454, 28-32.	1.1	134
33	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1385-1393.	6.3	127
34	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. <i>Current Opinion in Immunology</i> , 2014, 27, 89-97.	5.5	111
35	Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. <i>Annals of Oncology</i> , 2011, 22, 2646-2653.	1.2	109
36	Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1223-1233.	4.2	107

#	ARTICLE	IF	CITATIONS
37	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. <i>Annals of Oncology</i> , 2018, 29, 1312-1319.	1.2	106
38	Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 383-390.	8.7	100
39	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
40	Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future Research. <i>Gynecologic Oncology</i> , 2002, 84, 201-209.	1.4	89
41	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. <i>Annals of Oncology</i> , 2019, 30, 281-289.	1.2	88
42	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	7.7	80
43	Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma. <i>Clinical Cancer Research</i> , 2008, 14, 6895-6906.	7.0	79
44	Identification of TNF- α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. <i>British Journal of Cancer</i> , 2009, 101, 1876-1883.	6.4	79
45	A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 71-76.	2.5	78
46	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e86263.	2.5	76
47	Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes. <i>Oncologist</i> , 2011, 16, 877-885.	3.7	75
48	Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2058-2065.	6.4	75
49	Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1539-1545.	2.3	74
50	TGF β 2 Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 621-631.	4.1	68
51	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. <i>Nature Cancer</i> , 2020, 1, 75-85.	13.2	68
52	Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 T 2010, 11, 350-357.	10.7	64
53	Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: Safety and efficacy results from phase II.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4550-4550.	1.6	60
54	Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. <i>Journal of Immunology</i> , 2011, 187, 6130-6142.	0.8	59

#	ARTICLE	IF	CITATIONS
55	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. <i>Oncolimmunology</i> , 2016, 5, e1062967.	4.6	52
56	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-“PD-1 for patients with anti-“PD-1-“refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	51
57	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	7.2	51
58	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA); Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 2017, 18, 672-681a.	10.7	49
59	Liquid Biopsy: From Basic Research to Clinical Practice. <i>Advances in Clinical Chemistry</i> , 2018, 83, 73-119.	3.7	49
60	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp>8. <i>Journal of Pathology</i> , 2021, 255, 190-201.	4.5	49
61	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. <i>Journal of Clinical Investigation</i> , 2016, 127, 153-168.	8.2	49
62	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-“PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	1.1	48
63	<i>In vivo</i> depletion of DC impairs the anti-“tumor effect of agonistic anti-“CD137 mAb. <i>European Journal of Immunology</i> , 2009, 39, 2424-2436.	2.9	47
64	IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 355-355.	1.6	45
65	Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1312-1314.	9.4	41
66	A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. , 2018, 6, 96.		40
67	External-Beam Radiation Therapy and High-“Dose Rate Brachytherapy Combined With Long-Term Androgen Deprivation Therapy in High and Very High Prostate Cancer: Preliminary Data on Clinical Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e469-e476.	0.8	39
68	Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication. <i>Molecular Therapy</i> , 2006, 14, 129-138.	8.2	38
69	Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1621-1631.	4.2	38
70	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. <i>Tumor Biology</i> , 2016, 37, 13687-13694.	1.8	37
71	Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation. <i>PLoS ONE</i> , 2011, 6, e17922.	2.5	36
72	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018, 73, 462-468.	1.9	36

#	ARTICLE	IF	CITATIONS
73	Immunotherapy and immunescape in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 5822.	3.3	36
74	Selection of extreme phenotypes: the role of clinical observation in translational research. <i>Clinical and Translational Oncology</i> , 2010, 12, 174-180.	2.4	34
75	Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. <i>Brachytherapy</i> , 2017, 16, 1246-1251.	0.5	32
76	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. <i>International Journal of Cancer</i> , 2019, 145, 1991-2001.	5.1	32
77	PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).. <i>Journal of Clinical Oncology</i> , 2016, 34, 104-104.	1.6	32
78	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5012-5012.	1.6	30
79	A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients. <i>Journal of Pathology</i> , 2018, 245, 421-432.	4.5	29
80	Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4523-4523.	1.6	29
81	Dendritic Cells Take up and Present Antigens from Viable and Apoptotic Polymorphonuclear Leukocytes. <i>PLoS ONE</i> , 2011, 6, e29300.	2.5	27
82	Immunogenic Cell Death and Cross-Priming Are Reaching the Clinical Immunotherapy Arena: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 2385-2389.	7.0	25
83	The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research. <i>Cancer</i> , 2002, 95, 1605-1610.	4.1	24
84	Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer. <i>Onkologie</i> , 2009, 32, 580-584.	0.8	24
85	Phase II study of gemcitabine and cisplatin in chemo-naïve patients with advanced epithelial ovarian cancer. <i>Anti-Cancer Drugs</i> , 2002, 13, 839-845.	1.4	23
86	Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon- α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. <i>Annals of Oncology</i> , 2009, 20, 1803-1812.	1.2	23
87	Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 599-615.	3.1	22
88	Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.. <i>Radiation Oncology</i> , 2012, 7, 50.	2.7	21
89	Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. <i>Gene Therapy</i> , 2008, 15, 473-483.	4.5	20
90	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. <i>Clinica Chimica Acta</i> , 2014, 429, 168-174.	1.1	20

#	ARTICLE	IF	CITATIONS
91	A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 349-349.	1.6	19
92	Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. Clinical and Translational Oncology, 2014, 16, 322-329.	2.4	18
93	Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e1133-e1139.	1.9	18
94	A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.. Journal of Clinical Oncology, 2016, 34, 3056-3056.	1.6	18
95	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. Immunotherapy, 2009, 1, 845-853.	2.0	17
96	The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN γ . International Journal of Cancer, 2007, 121, 1282-1295.	5.1	16
97	Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes <i>in vitro</i> and <i>in vivo</i>. International Journal of Cancer, 2011, 129, 374-386.	5.1	16
98	A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Annals of Oncology, 2017, 28, 1517-1522.	1.2	16
99	Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinum-Based Chemotherapy. Oncologist, 2007, 12, 1151-1155.	3.7	15
100	Functional expression of CD137 (4-1BB) on T helper follicular cells. OncoImmunology, 2015, 4, e1054597.	4.6	15
101	SEOM clinical guideline for treatment of kidney cancer (2017). Clinical and Translational Oncology, 2018, 20, 47-56.	2.4	15
102	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. ESMO Open, 2020, 5, e000662.	4.5	15
103	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. Translational Research, 2021, 233, 77-91.	5.0	15
104	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clinical Cancer Research, 2018, 24, 6115-6124.	7.0	14
105	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1-expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. Journal of Clinical Oncology, 2017, 35, 9090-9090.	1.6	14
106	Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World Journal of Gastroenterology, 2009, 15, 2290.	3.3	14
107	Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clinical and Translational Oncology, 2013, 15, 698-704.	2.4	13
108	Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy, 2016, 15, 127-135.	0.5	13

#	ARTICLE	IF	CITATIONS
109	The Dynamic Use of <i>EGFR</i> Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients. <i>Disease Markers</i> , 2019, 2019, 1-7.	1.3	13
110	579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2021, 32, S629-S630.	1.2	13
111	Activity of Gefitinib in Central Nervous System Metastases in Patients with Non-Small-Cell Lung Cancer: Two Case Reports and a Review of the Literature. <i>Clinical Lung Cancer</i> , 2005, 7, 138-140.	2.6	12
112	Non-O1 <i>Vibrio cholerae</i> inguinal skin and soft tissue infection with bullous skin lesions in a patient with a penis squamous cell carcinoma. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2009, 8, 17.	3.8	12
113	Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). <i>Clinical and Translational Oncology</i> , 2012, 14, 564-574.	2.4	12
114	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. <i>Cancer Medicine</i> , 2018, 7, 3474-3483.	2.8	11
115	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 107, 186-195.	2.8	11
116	Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 452-460.	1.9	11
117	Variations in Molecular Profile in NSCLC Can Be Analyzed Using Cytological Samples. <i>International Journal of Surgical Pathology</i> , 2015, 23, 111-115.	0.8	10
118	HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4635-4643.	2.0	10
119	Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC. <i>Journal of Clinical Oncology</i> , 2016, 34, 9015-9015.	1.6	10
120	Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism. <i>Oncolimmunology</i> , 2012, 1, 1527-1536.	4.6	8
121	Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study. <i>Annals of Oncology</i> , 2016, 27, vi270.	1.2	8
122	Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer. <i>Clinical and Translational Oncology</i> , 2016, 18, 743-747.	2.4	8
123	Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?. <i>Translational Lung Cancer Research</i> , 2018, 7, S356-S357.	2.8	8
124	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii732.	1.2	8
125	Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e89747.	2.5	8
126	Assessment of the value of confirming responses in clinical trials in oncology. <i>European Journal of Cancer</i> , 2005, 41, 1528-1532.	2.8	7

#	ARTICLE	IF	CITATIONS
127	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4â€“1BB). <i>Oncolmmunology</i> , 2018, 7, e1368605.	4.6	7
128	A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkinâ€™s lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3107-TPS3107.	1.6	7
129	Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9024-9024.	1.6	7
130	Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1341-1348.	2.3	7
131	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institutionâ€™s experience. <i>Clinical and Translational Oncology</i> , 2012, 14, 835-841.	2.4	6
132	PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumorâ€™Samples for PD-L1 Assessment. <i>Journal of Thoracic Oncology</i> , 2016, 11, S174-S175.	1.1	6
133	Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1â€™expressing NSCLC: Updated outcomes of KEYNOTE-010. <i>Annals of Oncology</i> , 2016, 27, vi583.	1.2	6
134	Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients. <i>Cytokine</i> , 2021, 141, 155471.	3.2	6
135	Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 394-394.	1.6	6
136	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. <i>Clinical and Translational Oncology</i> , 2021, 23, 882-891.	2.4	5
137	Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp I± in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/metastatic renal cell carcinoma (RCC) (NCT03063762).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4556-4556.	1.6	5
138	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091.	3.1	4
139	Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. <i>Oncolmmunology</i> , 2020, 9, 1760676.	4.6	4
140	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3030-3030.	1.6	4
141	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 323-323.	1.6	4
142	Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 264-264.	1.6	4
143	A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 95-95.	1.6	4
144	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. <i>Bone Marrow Transplantation</i> , 2001, 27, 117-123.	2.4	3

#	ARTICLE	IF	CITATIONS
145	Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 651-654.	1.0	3
146	Radium-223 international early access program: results from the Spanish subset. <i>Future Oncology</i> , 2018, 14, 41-50.	2.4	3
147	Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1327-1337.	2.8	3
148	Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2R β null immunodeficient mice. , 2015, , .		3
149	First-in-human clinical trial with intratumoral BO-112 in solid malignancies: A novel immunotherapy based in double-stranded RNA (dsRNA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3082-3082.	1.6	3
150	Lymphocytes and neutrophils count after two cycles and TTF1 expression as early outcome predictors during immunotherapy (IT) in stage IV non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20553-e20553.	1.6	3
151	Polly Matzinger's "danger model" finds its predicted danger-denoting self moieties. <i>Immunologia (Barcelona, Spain: 1987)</i> , 2008, 27, 205-211.	0.1	2
152	Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2008, 10, 372-374.	2.4	1
153	Abstract CT017: Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. , 2018, , .		1
154	Identification through genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) associated with extreme phenotypes of tobacco-induced non-small cell lung cancer (NSCLC) risk.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11046-11046.	1.6	1
155	Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11010-11010.	1.6	1
156	Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung adenocarcinoma (LUAD) according to KRAS status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1540-1540.	1.6	1
157	6 The Role of extreme phenotype selection in cancer research. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2002, , 65-71.	0.0	0
158	SEOM clinical guidelines for using molecular markers in clinical practice. <i>Clinical and Translational Oncology</i> , 2011, 13, 587-591.	2.4	0
159	Phase Ii Study with Immunotherapy with Dendritic Cells (Dc) Combined with Intratumoral Hiltonol in Patients with Advanced Cancer. <i>Annals of Oncology</i> , 2014, 25, iv371.	1.2	0
160	Genome Wide Association Study (Gwas) for Identification of Single Nucleotide Polymorphisms (Snps) Associated with Individuals Presenting Extreme Phenotypes of Tobacco Induced Non-Small Cell Lung Cancer (Nslcl) Risk. <i>Annals of Oncology</i> , 2014, 25, iv548.	1.2	0
161	Id1 and Id3 genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver and increases survival. <i>Annals of Oncology</i> , 2016, 27, vi440.	1.2	0
162	PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.4	0

#	ARTICLE	IF	CITATIONS
163	Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Lorient, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>Eur Urol</i> 2018;73:462-468. <i>European Urology</i> , 2018, 74, e14.	1.9	0
164	Phase II study of paclitaxel and TAK-228 in metastatic urothelial carcinoma and the impact of PI3K-mTOR pathway genomic alterations. <i>Annals of Oncology</i> , 2018, 29, viii326.	1.2	0
165	International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1809-1813.	4.2	0
166	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. <i>Medical Oncology</i> , 2019, 36, 29.	2.5	0
167	Designing clinical studies for biomarker discovery: The Design criteria. , 2020, , 441-466.		0
168	Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4577-4577.	1.6	0
169	Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 145-145.	1.6	0
170	Vinflunine maintenance therapy versus best supportive care (BSC) after platinum combination in advanced bladder cancer: A phase II, randomized, open-label study (MAJA study)â€”SOGUG 2011-02.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4674-TPS4674.	1.6	0
171	EGFR-activating mutations and treatment with tyrosine-kinase inhibitors (TKI) to revert poor-prognosis (PP) associated with liver metastases (LM) in stage IV non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2013, 31, e19106-e19106.	1.6	0
172	Clinical validation of mutational analysis of EGFR and KRAS in fine needle aspiration and small core needle biopsies using a real-time PCR method.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19027-e19027.	1.6	0
173	Adrenalectomy for low-tumor-burden metastatic lung cancer: Results of a single institution experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19114-e19114.	1.6	0
174	Randomized phase II study with dendritic cell (DC) immunotherapy in patients with resected hepatic metastasis of colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3129-TPS3129.	1.6	0
175	Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3113-TPS3113.	1.6	0
176	Serum interleukin-8 and its relationship to tumor burden and treatment response across malignancies of multiple tissue origins.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22135-e22135.	1.6	0
177	Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8083-8083.	1.6	0
178	Abstract 954: Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib. , 2014, , .		0
179	Determining viability of circulating tumor cells (CTCs) as a predictive biomarker for response in patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with Radium 223 (Ra).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16051-e16051.	1.6	0
180	Familial clustering of lung cancer (LC) cases in a south European population (sEp).. <i>Journal of Clinical Oncology</i> , 2015, 33, e12621-e12621.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: A Spanish Oncology Genitourinary Group (SOGUC) study.. Journal of Clinical Oncology, 2016, 34, 4571-4571.	1.6	0
182	Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 4527-4527.	1.6	0
183	Unnecessary test ordering in clinical trials: human chorionic gonadotropin as an example. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	0
184	Molecular biomarkers of prognosis in advanced renal cell carcinoma patients treated with Pazopanib plus interferon alpha (INF-2A) in a phase I/II study by the Spanish Oncology Genitourinary Group. Clinical Genitourinary Cancer, 2022, , .	1.9	0